|
|
In this Cleveland Clinic Heart, Vascular & Thoracic Institute Grand Rounds, Dr. Milind Desai provides an overview of hypertrophic cardiomyopathy, advances in diagnostic evaluation and…
|
|
|
Presented at ACC as a Late-Breaking Clinical Trial, VALOR-HCM explores Mavacamten as an alternative to surgical septal myectomy or alcohol ablation in patients with severely symptomatic obstructive…
|
|
|
Alcohol septal ablation has been performed at Cleveland Clinic since the late 1980’s. Dr. Samir Kapadia describes optimal patients to undergo this procedure and outcomes of septal ablation vs.…
|
|
|
Dr. Nicholas Smedira, Surgical Director of the Hypertrophic Cardiomyopathy Center at Cleveland Clinic demonstrates the extended septal myectomy in a patient with hypertrophic cardiomyopathy.
|
|
|
Dr. Steven Nissen, Chief Academic Officer, Chief Academic Officer, Sydell and Arnold Miller Family Heart & Vascular Institute talks about cardiomyopathy with Wilson Tang, MD, Director of…
|
|
|
Steven Nissen, MD, Chairman of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine at Cleveland Clinic discusses hypertrophic cardiomyopathy (HCM) with experts: cardiologist Milind…
|
|
|
Dr. Mazen Hanna describes the findings of ATTR-ACT, a study aimed at the treatment of transthyretin (TTR) amyloid cardiomyopathy with the medication tafamadis. Those who were treated with the…
|
|
|
Dr. Desai describes the findings of over 1800 patients obstructive HCM in which they reviewed the 5-year primary event rate across the 3 ESC SCD risk categories. The results of this paper shows that…
|